Immunoadjuvants for cancer immunotherapy: A review of recent developments.
Identifieur interne : 000137 ( Main/Exploration ); précédent : 000136; suivant : 000138Immunoadjuvants for cancer immunotherapy: A review of recent developments.
Auteurs : Asmita Banstola [Corée du Sud] ; Jee-Heon Jeong [Corée du Sud] ; Simmyung Yook [Corée du Sud]Source :
- Acta biomaterialia [ 1878-7568 ] ; 2020.
Abstract
Cancer immunotherapy evolved as a new treatment modality to eradicate tumor cells and has gained in popularity after its successful clinical transition. By activating antigen-presenting cells (APCs), and thus, inducing innate or adaptive immune responses, immunoadjuvants have become promising tools for cancer immunotherapy. Different types of immunoadjuvants such as toll-like receptor (TLR) agonists, exosomes, and metallic and plant-derived immunoadjuvants have been studied for their immunological effects. However, the clinical use of immunoadjuvants is limited by short response rates and various side-effects. The rapid progress made in the development of nanoparticle systems as immunoadjuvant carrier vehicles has provided potential carriers for cancer immunotherapy. In this review article, we describe different types of immunoadjuvants, their limitations, modes of action, and the reasons for their clinical adoption. In addition, we review recent progress made in the nanoparticle-based immunoadjuvant field and on the combined use of nanoparticle-based immunoadjuvants and chemotherapy, phototherapy, radiation therapy, and immune checkpoint inhibitor-based therapy. STATEMENT OF SIGNIFICANCE: Cancer immunotherapy emerged as a new hope for treating malignant tumors. Different types of immunoadjuvants serve as an important tool for cancer immunotherapy by activating an innate or adaptive immune response. Limitation of free immunoadjuvant has paved the path for the development of nanoparticle-based immunoadjuvant therapy with the hope of prolonging the therapeutic efficacy. This review highlights the recent advancement made in nanoparticle-based immunoadjuvant therapy in modulating the adaptive and innate immune system. The application of the combinatorial approach of chemotherapy, phototherapy, radiation therapy adds synergy in nanoparticle-based immunoadjuvant therapy. It will broaden the reader's understanding on the recent progress made in immunotherapy with the aid of immunoadjuvant-based nanosystem.
DOI: 10.1016/j.actbio.2020.07.063
PubMed: 32777293
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunoadjuvants for cancer immunotherapy: A review of recent developments.</title><author><name sortKey="Banstola, Asmita" sort="Banstola, Asmita" uniqKey="Banstola A" first="Asmita" last="Banstola">Asmita Banstola</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Keimyung University, Daegu, 42601</wicri:regionArea><wicri:noRegion>42601</wicri:noRegion></affiliation></author><author><name sortKey="Jeong, Jee Heon" sort="Jeong, Jee Heon" uniqKey="Jeong J" first="Jee-Heon" last="Jeong">Jee-Heon Jeong</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Republic of Korea. Electronic address: jeeheon@yu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 38541</wicri:regionArea><wicri:noRegion>Gyeongbuk 38541</wicri:noRegion></affiliation></author><author><name sortKey="Yook, Simmyung" sort="Yook, Simmyung" uniqKey="Yook S" first="Simmyung" last="Yook">Simmyung Yook</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea. Electronic address: ysimmyung@kmu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Keimyung University, Daegu, 42601</wicri:regionArea><wicri:noRegion>42601</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32777293</idno><idno type="pmid">32777293</idno><idno type="doi">10.1016/j.actbio.2020.07.063</idno><idno type="wicri:Area/Main/Corpus">000074</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000074</idno><idno type="wicri:Area/Main/Curation">000074</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000074</idno><idno type="wicri:Area/Main/Exploration">000074</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunoadjuvants for cancer immunotherapy: A review of recent developments.</title><author><name sortKey="Banstola, Asmita" sort="Banstola, Asmita" uniqKey="Banstola A" first="Asmita" last="Banstola">Asmita Banstola</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Keimyung University, Daegu, 42601</wicri:regionArea><wicri:noRegion>42601</wicri:noRegion></affiliation></author><author><name sortKey="Jeong, Jee Heon" sort="Jeong, Jee Heon" uniqKey="Jeong J" first="Jee-Heon" last="Jeong">Jee-Heon Jeong</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Republic of Korea. Electronic address: jeeheon@yu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 38541</wicri:regionArea><wicri:noRegion>Gyeongbuk 38541</wicri:noRegion></affiliation></author><author><name sortKey="Yook, Simmyung" sort="Yook, Simmyung" uniqKey="Yook S" first="Simmyung" last="Yook">Simmyung Yook</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea. Electronic address: ysimmyung@kmu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Keimyung University, Daegu, 42601</wicri:regionArea><wicri:noRegion>42601</wicri:noRegion></affiliation></author></analytic><series><title level="j">Acta biomaterialia</title><idno type="eISSN">1878-7568</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cancer immunotherapy evolved as a new treatment modality to eradicate tumor cells and has gained in popularity after its successful clinical transition. By activating antigen-presenting cells (APCs), and thus, inducing innate or adaptive immune responses, immunoadjuvants have become promising tools for cancer immunotherapy. Different types of immunoadjuvants such as toll-like receptor (TLR) agonists, exosomes, and metallic and plant-derived immunoadjuvants have been studied for their immunological effects. However, the clinical use of immunoadjuvants is limited by short response rates and various side-effects. The rapid progress made in the development of nanoparticle systems as immunoadjuvant carrier vehicles has provided potential carriers for cancer immunotherapy. In this review article, we describe different types of immunoadjuvants, their limitations, modes of action, and the reasons for their clinical adoption. In addition, we review recent progress made in the nanoparticle-based immunoadjuvant field and on the combined use of nanoparticle-based immunoadjuvants and chemotherapy, phototherapy, radiation therapy, and immune checkpoint inhibitor-based therapy. STATEMENT OF SIGNIFICANCE: Cancer immunotherapy emerged as a new hope for treating malignant tumors. Different types of immunoadjuvants serve as an important tool for cancer immunotherapy by activating an innate or adaptive immune response. Limitation of free immunoadjuvant has paved the path for the development of nanoparticle-based immunoadjuvant therapy with the hope of prolonging the therapeutic efficacy. This review highlights the recent advancement made in nanoparticle-based immunoadjuvant therapy in modulating the adaptive and innate immune system. The application of the combinatorial approach of chemotherapy, phototherapy, radiation therapy adds synergy in nanoparticle-based immunoadjuvant therapy. It will broaden the reader's understanding on the recent progress made in immunotherapy with the aid of immunoadjuvant-based nanosystem.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">32777293</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7568</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><PubDate><Year>2020</Year><Month>09</Month><Day>15</Day></PubDate></JournalIssue><Title>Acta biomaterialia</Title><ISOAbbreviation>Acta Biomater</ISOAbbreviation></Journal><ArticleTitle>Immunoadjuvants for cancer immunotherapy: A review of recent developments.</ArticleTitle><Pagination><MedlinePgn>16-30</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1742-7061(20)30461-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.actbio.2020.07.063</ELocationID><Abstract><AbstractText>Cancer immunotherapy evolved as a new treatment modality to eradicate tumor cells and has gained in popularity after its successful clinical transition. By activating antigen-presenting cells (APCs), and thus, inducing innate or adaptive immune responses, immunoadjuvants have become promising tools for cancer immunotherapy. Different types of immunoadjuvants such as toll-like receptor (TLR) agonists, exosomes, and metallic and plant-derived immunoadjuvants have been studied for their immunological effects. However, the clinical use of immunoadjuvants is limited by short response rates and various side-effects. The rapid progress made in the development of nanoparticle systems as immunoadjuvant carrier vehicles has provided potential carriers for cancer immunotherapy. In this review article, we describe different types of immunoadjuvants, their limitations, modes of action, and the reasons for their clinical adoption. In addition, we review recent progress made in the nanoparticle-based immunoadjuvant field and on the combined use of nanoparticle-based immunoadjuvants and chemotherapy, phototherapy, radiation therapy, and immune checkpoint inhibitor-based therapy. STATEMENT OF SIGNIFICANCE: Cancer immunotherapy emerged as a new hope for treating malignant tumors. Different types of immunoadjuvants serve as an important tool for cancer immunotherapy by activating an innate or adaptive immune response. Limitation of free immunoadjuvant has paved the path for the development of nanoparticle-based immunoadjuvant therapy with the hope of prolonging the therapeutic efficacy. This review highlights the recent advancement made in nanoparticle-based immunoadjuvant therapy in modulating the adaptive and innate immune system. The application of the combinatorial approach of chemotherapy, phototherapy, radiation therapy adds synergy in nanoparticle-based immunoadjuvant therapy. It will broaden the reader's understanding on the recent progress made in immunotherapy with the aid of immunoadjuvant-based nanosystem.</AbstractText><CopyrightInformation>Copyright © 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banstola</LastName><ForeName>Asmita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Jee-Heon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Republic of Korea. Electronic address: jeeheon@yu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yook</LastName><ForeName>Simmyung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea. Electronic address: ysimmyung@kmu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Biomater</MedlineTA><NlmUniqueID>101233144</NlmUniqueID><ISSNLinking>1742-7061</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Exosome</Keyword><Keyword MajorTopicYN="Y">Immune checkpoint inhibitor</Keyword><Keyword MajorTopicYN="Y">Immunoadjuvant</Keyword><Keyword MajorTopicYN="Y">Phototherapy</Keyword><Keyword MajorTopicYN="Y">Toll-like receptor</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest There is no conflict of interest and disclosure associated with the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32777293</ArticleId><ArticleId IdType="pii">S1742-7061(20)30461-X</ArticleId><ArticleId IdType="doi">10.1016/j.actbio.2020.07.063</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country></list><tree><country name="Corée du Sud"><noRegion><name sortKey="Banstola, Asmita" sort="Banstola, Asmita" uniqKey="Banstola A" first="Asmita" last="Banstola">Asmita Banstola</name></noRegion><name sortKey="Jeong, Jee Heon" sort="Jeong, Jee Heon" uniqKey="Jeong J" first="Jee-Heon" last="Jeong">Jee-Heon Jeong</name><name sortKey="Yook, Simmyung" sort="Yook, Simmyung" uniqKey="Yook S" first="Simmyung" last="Yook">Simmyung Yook</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000137 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000137 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32777293
|texte= Immunoadjuvants for cancer immunotherapy: A review of recent developments.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32777293" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |